Search

Your search keyword '"Kroeger, N."' showing total 31 results
Start Over Author "Kroeger, N." Publisher nature publishing group
31 results on '"Kroeger, N."'

1. Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

Author

Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S., Schetelig, J., Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S., and Schetelig, J.

Published
2017

2. The impact of melphalan dosage on outcomes of autologous haematopoietic cell transplantation for multiple myeloma: Results from the EBMT collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study

Author

Auner, H., Iacobelli, S., Bianchi, G., Knol-Bout, C., Blaise, D., Russell, N., Apperley, J., Pohlreich, D., Browne, P., Kobbe, G., Isaksson, C., Lenhoff, S., Scheid, C., Chevallier, P., Jantunen, E., Anagnostopoulos, A., Yakoub-Agha, I., Tanase, A., Schaap, N., Wiktor-Jedrzejczak, W., Mayer, J., Schoenland, S., Morris, C., Garderet, L., Kroeger, N., Auner, H., Iacobelli, S., Bianchi, G., Knol-Bout, C., Blaise, D., Russell, N., Apperley, J., Pohlreich, D., Browne, P., Kobbe, G., Isaksson, C., Lenhoff, S., Scheid, C., Chevallier, P., Jantunen, E., Anagnostopoulos, A., Yakoub-Agha, I., Tanase, A., Schaap, N., Wiktor-Jedrzejczak, W., Mayer, J., Schoenland, S., Morris, C., Garderet, L., and Kroeger, N.

Published
2017

3. Outcomes after matched unrelated donor and non-T-cell depleted haploidentical stem cell transplantation in patients >= 60 years with acute myeloid leukemia: A comparative study on behalf of the ALWP of the EBMT

Author

Giannotti, F., Labopin, M., Ruggeri, A., Ehninger, G., Niederwieser, D., Stelljes, M., Stuhler, G., Kroeger, N., Einsele, H., Eder, M., Hallek, M., Glass, B., Finke, J., Ciceri, F., Mohty, M., Nagler, A., Giannotti, F., Labopin, M., Ruggeri, A., Ehninger, G., Niederwieser, D., Stelljes, M., Stuhler, G., Kroeger, N., Einsele, H., Eder, M., Hallek, M., Glass, B., Finke, J., Ciceri, F., Mohty, M., and Nagler, A.

Published
2017

4. Outcome of the rare myeloma subtypes: An analysis of the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) data

Author

Lawless, S., Morris, C., Iacobelli, S., Bianchi, G., Bosman, P., Blaise, D., Remenyi, P., Russell, N. H., Mayer, J., Apperley, J., Ljungman, P., Kobbe, G., Schaap, N., Isaksson, C., Lenhoff, S., Wiktor-Jedrzejczak, W., Chevallier, P., Wilson, K. M. O., Muniz, S. G., Scheid, C., Schoenland, S., Garderet, L., Kroeger, N., Lawless, S., Morris, C., Iacobelli, S., Bianchi, G., Bosman, P., Blaise, D., Remenyi, P., Russell, N. H., Mayer, J., Apperley, J., Ljungman, P., Kobbe, G., Schaap, N., Isaksson, C., Lenhoff, S., Wiktor-Jedrzejczak, W., Chevallier, P., Wilson, K. M. O., Muniz, S. G., Scheid, C., Schoenland, S., Garderet, L., and Kroeger, N.

Published
2017

5. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party

Author

Scheid, C., de Wreede, L., van Biezen, A., Koenecke, C., Gohring, G., Volin, L., Maertens, J., Finke, J., Passweg, J., Beelen, D., Cornelissen, J. J., Itaelae-Remes, M., Chevallier, P., Russell, N., Petersen, E., Milpied, N., Espiga, C. Richard, Peniket, A., Sierra, J., Mufti, G., Crawley, C., Veelken, J. H., Ljungman, P., Cahn, J. Y., Alessandrino, E. P., de Witte, T., Robin, M., Kroeger, N., Scheid, C., de Wreede, L., van Biezen, A., Koenecke, C., Gohring, G., Volin, L., Maertens, J., Finke, J., Passweg, J., Beelen, D., Cornelissen, J. J., Itaelae-Remes, M., Chevallier, P., Russell, N., Petersen, E., Milpied, N., Espiga, C. Richard, Peniket, A., Sierra, J., Mufti, G., Crawley, C., Veelken, J. H., Ljungman, P., Cahn, J. Y., Alessandrino, E. P., de Witte, T., Robin, M., and Kroeger, N.

Abstract

The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P < 0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P < 0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.

Published
2017

6. Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation

Author

Greinix, H., Beohou, E., van der Werf, S., Niederwieser, D., Blaise, D., Dreger, P., Arnold, R., Meijer, E., Sengeloev, H., Cornelissen, J., Hallek, M., Socie, G., Chevallier, P., Ganser, A., Milpied, N., Maertens, J., Petersen, E., Afanasyev, B., Ehninger, G., Fegueux, N., Jindra, P., Kroeger, N., Montoto, S., Nagler, A., Duarte, R., Greinix, H., Beohou, E., van der Werf, S., Niederwieser, D., Blaise, D., Dreger, P., Arnold, R., Meijer, E., Sengeloev, H., Cornelissen, J., Hallek, M., Socie, G., Chevallier, P., Ganser, A., Milpied, N., Maertens, J., Petersen, E., Afanasyev, B., Ehninger, G., Fegueux, N., Jindra, P., Kroeger, N., Montoto, S., Nagler, A., and Duarte, R.

Published
2017

7. No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties

Author

Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Parody Porras, R., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroeger, N., Schetelig, J., Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Parody Porras, R., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroeger, N., and Schetelig, J.

Published
2017

8. Outcomes of mismatched related allogeneic stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Author

van Gorkom, G., van Gelder, M., Ziagkos, D., Koster, L., Koc, Y., van Lint, M., Ciceri, F., Selleslag, D., Blaise, D., Foa, R., Beelen, D., Corradini, P., Moreno, C., Carlson, K., Solano, C., Mueller, L. P., Castagna, L., Tischer, J., Hilgendorf, I., Hallek, M., Bittenbring, J., Theobald, M., Schetelig, J., Kroeger, N., van Gorkom, G., van Gelder, M., Ziagkos, D., Koster, L., Koc, Y., van Lint, M., Ciceri, F., Selleslag, D., Blaise, D., Foa, R., Beelen, D., Corradini, P., Moreno, C., Carlson, K., Solano, C., Mueller, L. P., Castagna, L., Tischer, J., Hilgendorf, I., Hallek, M., Bittenbring, J., Theobald, M., Schetelig, J., and Kroeger, N.

Published
2016

9. Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with high-risk AML in complete remission: a survey from the ALWP of the EBMT

Author

Malard, F., Labopin, M., Stuhler, G., Bittenbring, J., Ganser, A., Tischer, J., Michallet, M., Kroeger, N., Schmid, C., Huynh, A., Hallek, M., Savani, B., Mohty, M., Nagler, A., Malard, F., Labopin, M., Stuhler, G., Bittenbring, J., Ganser, A., Tischer, J., Michallet, M., Kroeger, N., Schmid, C., Huynh, A., Hallek, M., Savani, B., Mohty, M., and Nagler, A.

Published
2016

10. Effects of Busulfan dose and administration route on transplantation outcome in adult patients with AML or MDS - a retrospective analysis of the German transplant registry DRST

Author

Scheid, C., Holtick, U., Bornhaeuser, M., Kroeger, N., Ganser, A., Arnold, R., Dreger, P., Stuhler, G., Theobald, M., Peschel, C., Hallek, M., Niederwieser, D., Finke, J., Hertenstein, B., Beelen, D., Scheid, C., Holtick, U., Bornhaeuser, M., Kroeger, N., Ganser, A., Arnold, R., Dreger, P., Stuhler, G., Theobald, M., Peschel, C., Hallek, M., Niederwieser, D., Finke, J., Hertenstein, B., and Beelen, D.

Published
2015

11. High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers

Author

Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J., von Bubnoff, N., Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J., and von Bubnoff, N.

Published
2015

12. RIC vs. MAC followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the CMWP of the EBMT (RICMAC-Trial)

Author

Kroeger, N., Brand, R., Niederwieser, D., Platzbecker, U., Huebel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G. Lambertenghi, Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., van Os, M., Iacobelli, S., de Witte, T., Kroeger, N., Brand, R., Niederwieser, D., Platzbecker, U., Huebel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G. Lambertenghi, Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., van Os, M., Iacobelli, S., and de Witte, T.

Published
2015

13. Influence of HLA-matching after reduced intensity conditioning regimen and unrelated donor allo-SCT for acute leukemia in patients older than 50 years - a report from the acute leukemia working party of the EBMT

Author

Savani, B., Labopin, M., Polge, E., Niederwieser, D., Ganser, A., Ehninger, G., Bornhaeuser, M., Renate, A., Finke, J., Kroeger, N., Craddock, C., Schwerdtfeger, R., Hallek, M., Jindra, P., Mohty, M., Nagler, A., Savani, B., Labopin, M., Polge, E., Niederwieser, D., Ganser, A., Ehninger, G., Bornhaeuser, M., Renate, A., Finke, J., Kroeger, N., Craddock, C., Schwerdtfeger, R., Hallek, M., Jindra, P., Mohty, M., and Nagler, A.

Published
2015

14. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Author

Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J., von Bubnoff, N., Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J., and von Bubnoff, N.

Abstract

Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n = 54, all grades III or IV) or SR-cGVHD (n = 41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1-7) and SR-cGVHD (1-10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3-90.7%, 95% confidence interval (CI)) and 97.4% (92.3-100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.

Published
2015

15. Targeted drug delivery using genetically engineered diatom biosilica

Author

Delalat, B, Sheppard, VC, Ghaemi, SR, Rao, S, Prestidge, CA, McPhee, G, Rogers, M-L, Donoghue, JF, Pillay, V, Johns, TG, Kroeger, N, Voelcker, NH, Delalat, B, Sheppard, VC, Ghaemi, SR, Rao, S, Prestidge, CA, McPhee, G, Rogers, M-L, Donoghue, JF, Pillay, V, Johns, TG, Kroeger, N, and Voelcker, NH

Abstract

The ability to selectively kill cancerous cell populations while leaving healthy cells unaffected is a key goal in anticancer therapeutics. The use of nanoporous silica-based materials as drug-delivery vehicles has recently proven successful, yet production of these materials requires costly and toxic chemicals. Here we use diatom microalgae-derived nanoporous biosilica to deliver chemotherapeutic drugs to cancer cells. The diatom Thalassiosira pseudonana is genetically engineered to display an IgG-binding domain of protein G on the biosilica surface, enabling attachment of cell-targeting antibodies. Neuroblastoma and B-lymphoma cells are selectively targeted and killed by biosilica displaying specific antibodies sorbed with drug-loaded nanoparticles. Treatment with the same biosilica leads to tumour growth regression in a subcutaneous mouse xenograft model of neuroblastoma. These data indicate that genetically engineered biosilica frustules may be used as versatile 'backpacks' for the targeted delivery of poorly water-soluble anticancer drugs to tumour sites.

Published
2015

16. THE REVISED IPSS (IPSS-R) AT TRANSPLANT PREDICTS OVERALL AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MDS/SAML: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY

Author

Scheid, C., de Wreede, L., van Biezen, A., Goehring, G., Koenecke, C., Volin, L., Maertens, J., Finke, J., Schaap, N., Socie, G., Passweg, J., Cornelissen, J., Beelen, D., de Witte, T., Kroeger, N., Scheid, C., de Wreede, L., van Biezen, A., Goehring, G., Koenecke, C., Volin, L., Maertens, J., Finke, J., Schaap, N., Socie, G., Passweg, J., Cornelissen, J., Beelen, D., de Witte, T., and Kroeger, N.

Published
2014

17. IMPACT OF CYTOGENETIC USING THE IPSS REVISED CYTOGENETIC CLASSIFICATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS OR AML EVOLVING FROM MDS: A RETROSPECTIVE MULTICENTER STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT

Author

Koenecke, C., Goehring, G., de Wreede, L., van Biezen, A., Scheid, C., Volin, L., Maertens, J., Finke, J., Schaap, N. P. M., Robin, M., Passweg, J., Cornelissen, J., Beelen, D., Heuser, M., de Witte, T., Kroeger, N., Koenecke, C., Goehring, G., de Wreede, L., van Biezen, A., Scheid, C., Volin, L., Maertens, J., Finke, J., Schaap, N. P. M., Robin, M., Passweg, J., Cornelissen, J., Beelen, D., Heuser, M., de Witte, T., and Kroeger, N.

Published
2014

19. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

Author

Mohty, M., Huebel, K., Kroeger, N., Aljurf, M., Apperley, J., Basak, G. W., Bazarbachi, A., Douglas, K., Gabriel, I., Garderet, L., Geraldes, C., Jaksic, O., Kattan, M. W., Koristek, Z., Lanza, F., Lemoli, R. M., Mendeleeva, L., Mikala, G., Mikhailova, N., Nagler, A., Schouten, H. C., Selleslag, D., Suciu, S., Sureda, A., Worel, N., Wuchter, P., Chabannon, C., Duarte, R. F., Mohty, M., Huebel, K., Kroeger, N., Aljurf, M., Apperley, J., Basak, G. W., Bazarbachi, A., Douglas, K., Gabriel, I., Garderet, L., Geraldes, C., Jaksic, O., Kattan, M. W., Koristek, Z., Lanza, F., Lemoli, R. M., Mendeleeva, L., Mikala, G., Mikhailova, N., Nagler, A., Schouten, H. C., Selleslag, D., Suciu, S., Sureda, A., Worel, N., Wuchter, P., Chabannon, C., and Duarte, R. F.

Abstract

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

Published
2014

20. The Phaeodactylum genome reveals the evolutionary history of diatom genomes

Author

Bowler, C., Allen, A.E., Badger, J.H., Grimwood, J., Jabbari, K., Kup, A., Maheswari, U., Martens, C., Maumus, F., Ottilar, R.P., Rayko, E., Salamov, A., Vandepoele, K., Beszteri, B., Gruber, A., Heijde, M., Katinka, M., Mock, T., Valentin, K., Verret, F., Berges, J.A., Brownlee, C., Cadoret, J.-P., Chiovitti, A., Choi, C.J., Coesel, S., De Martino, A., Detter, J.C., Durkin, C., Falciatore, A., Fournet, J., Haruta, M., Huysmann, M., Jenkins, B.D., Jiroutova, K., Jorgensen, R.E., Joubert, Y., Kaplan, A., Kroeger, N., Kroth, P., LaRoche, Julie, Lindquist, E., Lommer, Markus, Martin-Jezequel, V., Lopez, P.J., Lucas, S., Mangogna, M., McGinnis, K., Medlin, L.K., Montsant, A., Oudot-Le Secq, M.-P., Napoli, C., Obornik, M., Petit, J.-L., Porcel, B.M., Poulsen, N., Robison, M., Rychlewski, L., Rynearson, T.A., Schmutz, J., Schnitzler Parker, M., Shapiro, H., Siaut, M., Stanley, M., Sussmann, M.J., Taylor, A., Vardi, A., von Dassow, P., Vyverman, W., Willis, A., Wyrwicz, L.S., Rokhsar, D.S., Weissenbach, J., Armbrust, E.V., Green, B.R., Van de Peer, Y., Grigoriev, I.V., Bowler, C., Allen, A.E., Badger, J.H., Grimwood, J., Jabbari, K., Kup, A., Maheswari, U., Martens, C., Maumus, F., Ottilar, R.P., Rayko, E., Salamov, A., Vandepoele, K., Beszteri, B., Gruber, A., Heijde, M., Katinka, M., Mock, T., Valentin, K., Verret, F., Berges, J.A., Brownlee, C., Cadoret, J.-P., Chiovitti, A., Choi, C.J., Coesel, S., De Martino, A., Detter, J.C., Durkin, C., Falciatore, A., Fournet, J., Haruta, M., Huysmann, M., Jenkins, B.D., Jiroutova, K., Jorgensen, R.E., Joubert, Y., Kaplan, A., Kroeger, N., Kroth, P., LaRoche, Julie, Lindquist, E., Lommer, Markus, Martin-Jezequel, V., Lopez, P.J., Lucas, S., Mangogna, M., McGinnis, K., Medlin, L.K., Montsant, A., Oudot-Le Secq, M.-P., Napoli, C., Obornik, M., Petit, J.-L., Porcel, B.M., Poulsen, N., Robison, M., Rychlewski, L., Rynearson, T.A., Schmutz, J., Schnitzler Parker, M., Shapiro, H., Siaut, M., Stanley, M., Sussmann, M.J., Taylor, A., Vardi, A., von Dassow, P., Vyverman, W., Willis, A., Wyrwicz, L.S., Rokhsar, D.S., Weissenbach, J., Armbrust, E.V., Green, B.R., Van de Peer, Y., and Grigoriev, I.V.

Abstract

Diatoms are photosynthetic secondary endosymbionts found throughout marine and freshwater environments, and are believed to be responsible for around one-fifth of the primary productivity on Earth1, 2. The genome sequence of the marine centric diatom Thalassiosira pseudonana was recently reported, revealing a wealth of information about diatom biology3, 4, 5. Here we report the complete genome sequence of the pennate diatom Phaeodactylum tricornutum and compare it with that of T. pseudonana to clarify evolutionary origins, functional significance and ubiquity of these features throughout diatoms. In spite of the fact that the pennate and centric lineages have only been diverging for 90 million years, their genome structures are dramatically different and a substantial fraction of genes (approx40%) are not shared by these representatives of the two lineages. Analysis of molecular divergence compared with yeasts and metazoans reveals rapid rates of gene diversification in diatoms. Contributing factors include selective gene family expansions, differential losses and gains of genes and introns, and differential mobilization of transposable elements. Most significantly, we document the presence of hundreds of genes from bacteria. More than 300 of these gene transfers are found in both diatoms, attesting to their ancient origins, and many are likely to provide novel possibilities for metabolite management and for perception of environmental signals. These findings go a long way towards explaining the incredible diversity and success of the diatoms in contemporary oceans.

Published
2008
Full Text
View/download PDF

21. Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party.

Author

Schoemans H, Burns LJ, Liptrott SJ, Murray J, Kenyon M, Barata A, Bolaños N, Scholl I, Hamilton B, Phelan R, Buchbinder D, Penack O, Moiseev I, Boreland W, Peczynski C, De Geest S, Sureda A, Snowden JA, Shaw B, Peric Z, and Kroeger N

Subjects
Humans, Male, Female, Cross-Sectional Studies, Surveys and Questionnaires, Middle Aged, Adult, Patient Reported Outcome Measures, Cell- and Tissue-Based Therapy methods, Hematopoietic Stem Cell Transplantation methods, Patient Participation
Abstract

The EBMT (European Blood and Marrow Transplantation Society) aims to connect patients, the scientific community, and other stakeholders to improve hematopoietic stem cell transplantation and cellular therapy outcomes. We performed a cross-sectional online survey to understand the perceptions regarding Patient Reported Outcomes (PROs) and Patient Active Involvement in Research (PAIR) in over 800 stakeholders (n = 813). Patients (n = 278) and health care professionals (HCPs) (n = 351) were compared. We observed high openness for EBMT PRO collection (n = 680, 84.5% across stakeholders' groups; patients n = 256, 93.1% versus HCPs n = 273, 78.4% [p < 0.001]) and PAIR (n = 702, 87.3% across stakeholder groups; patients n = 256, 92.4% versus HCPs n = 296, 85.8% [p = 0.009]), with a significantly higher proportion of patients expressing interest compared to HCPs. Priority domains for PROs data-collection identified were the assessment of symptom experience, psychosocial and cognitive functioning. The most important issues for patients specifically were the data-collection of PROs reflecting cognitive function, the option of reporting data at home, the importance of identifying actionable targets to improve their recovery, and receiving feedback on their input when participating in research projects. Our multistakeholder approach suggests an added value to embracing patient engagement in the development of meaningful research and service design within the transplantation and cellular therapy community., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2024
Full Text
View/download PDF

22. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.

Author

Averbuch D, de la Camara R, Tridello G, Knelange NS, Bykova TA, Ifversen M, Dobsinska V, Ayas M, Hamidieh AA, Pichler H, Perez-Martinez A, Cesaro S, Sundin M, Badell I, Bader P, Johansson JE, Mirci-Danicar O, Sedlacek P, Paillard C, Gibson B, Lawson S, Kroeger N, Corbacioglu S, Mikulska M, Piñana JL, Styczynski J, and Ljungman P

Subjects
Humans, Male, Child, Female, Transplantation, Homologous, Prospective Studies, Bone Marrow, COVID-19 Testing, Cough etiology, SARS-CoV-2, Risk Factors, Disease Progression, COVID-19 etiology, Hematopoietic Stem Cell Transplantation adverse effects, Communicable Diseases etiology
Abstract

Risk factors for severe SARS-Cov-2 infection course are poorly described in children following hematopoietic cell transplantation (HCT). In this international study, we analyzed factors associated with a severe course (intensive care unit (ICU) admission and/or mortality) in post-HCT children. Eighty-nine children (58% male; median age 9 years (min-max 1-18)) who received an allogeneic (85; 96%) or an autologous (4; 4%) HCT were reported from 28 centers (18 countries). Median time from HCT to SARS-Cov-2 infection was 7 months (min-max 0-181). The most common clinical manifestations included fever (37; 42%) and cough (26; 29%); 37 (42%) were asymptomatic. Nine (10%) children following allo-HCT required ICU care. Seven children (8%) following allo-HCT, died at a median of 22 days after SARS-Cov-2 diagnosis. In a univariate analysis, the probability of a severe disease course was higher in allo-HCT children with chronic GVHD, non-malignant disease, immune suppressive treatment (specifically, mycophenolate), moderate immunodeficiency score, low Lansky score, fever, cough, coinfection, pulmonary radiological findings, and high C-reactive protein. In conclusion, SARS-Cov-2 infection in children following HCT was frequently asymptomatic. Despite this, 10% needed ICU admission and 8% died in our cohort. Certain HCT, underlying disease, and SARS-Cov-2 related factors were associated with a severe disease course., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

23. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).

Author

Maffini E, Labopin M, Beelen DW, Kroeger N, Arat M, Wilson KMO, Bay JO, Ganser A, Martin H, Passweg J, Kottaridis PD, Yakoub-Agha I, Porras RP, Wagner EM, Esteve J, Lanza F, Nagler A, and Mohty M

Subjects
Acute Disease, Adult, Bone Marrow, Humans, Neoplasm, Residual, Recurrence, Retrospective Studies, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy, Neoplasms, Second Primary
Abstract

Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2022
Full Text
View/download PDF

24. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT.

Author

Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, Ganser A, Nagler A, Snowden JA, Robin M, Passweg J, Van Gorkom G, Wallet HL, Hoek J, Blok HJ, De Witte T, Kroeger N, Hayden P, Chalandon Y, and Agha IY

Subjects
Dasatinib adverse effects, Humans, Imatinib Mesylate adverse effects, Middle Aged, Prospective Studies, Protein Kinase Inhibitors adverse effects, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) remains a treatment option for patients with chronic myeloid leukemia (CML) who fail to respond to tyrosine kinase inhibitors (TKIs). While imatinib seems to have no adverse impact on outcomes after transplant, little is known on the effects of prior use of second-generation TKI (2GTKI). We present the results of a prospective non-interventional study performed by the EBMT on 383 consecutive CML patients previously treated with dasatinib or nilotinib undergoing allo-HCT from 2009 to 2013. The median age was 45 years (18-68). Disease status at transplant was CP1 in 139 patients (38%), AP or >CP1 in 163 (45%), and BC in 59 (16%). The choice of 2GTKI was: 40% dasatinib, 17% nilotinib, and 43% a sequential treatment of dasatinib and nilotinib with or without bosutinib/ponatinib. With a median follow-up of 37 months (1-77), 8% of patients developed either primary or secondary graft failure, 34% acute and 60% chronic GvHD. There were no differences in post-transplant complications between the three different 2GTKI subgroups. Non-relapse mortality was 18% and 24% at 12 months and at 5 years, respectively. Relapse incidence was 36%, overall survival 56% and relapse-free survival 40% at 5 years. No differences in post-transplant outcomes were found between the three different 2GTKI subgroups. This prospective study demonstrates the feasibility of allo-HCT in patients previously treated with 2GTKI with a post-transplant complications rate comparable to that of TKI-naive or imatinib-treated patients., (© 2021. The Author(s).)

Published
2022
Full Text
View/download PDF

25. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Author

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, and Putter H

Subjects
Accreditation, Australia, Belgium, Bone Marrow, Europe, France, Germany, Humans, Italy, Spain, Switzerland, United Kingdom, Benchmarking, Hematopoietic Stem Cell Transplantation
Abstract

In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.

Published
2020
Full Text
View/download PDF

26. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

Author

Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, and Aljurf M

Subjects
Bone Marrow, Developing Countries, Income, Biosimilar Pharmaceuticals, Hematopoietic Stem Cell Transplantation
Abstract

Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

Published
2020
Full Text
View/download PDF

27. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Author

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, and Putter H

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

28. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

Author

Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, and Aljurf M

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

29. Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.

Author

Neth OW, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuk F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston RM, Klein N, and Zander AR

Subjects
Adolescent, Adult, Aged, Disease Susceptibility, Female, Genotype, Graft vs Host Disease etiology, Graft vs Host Disease genetics, Humans, Male, Mannose-Binding Lectin blood, Middle Aged, Mycoses etiology, Phenotype, Prospective Studies, Retrospective Studies, Sepsis etiology, Stem Cell Transplantation mortality, Tissue Donors, Transplantation, Homologous, Mannose-Binding Lectin genetics, Stem Cell Transplantation adverse effects
Abstract

Mannan-binding lectin (MBL) deficiency is determined by MBL gene polymorphisms and is associated with an increased infection risk. To clarify the role of MBL in Allo-SCT, 131 recipients-donors were analysed. MBL genotypes were determined by PCR and heteroduplex analyses, MBL serum levels by ELISA, and MBL oligomers by western blotting. MBL levels <400 ng/ml were associated with increased susceptibility to fungal pneumonia (7/12 vs 35/111; P=0.04, adjusted P=0.002), HSV/VZV (7/12 vs 26/111; P=0.03), CMV reactivation and acute GVHD. Donor genotypes had no influence. Pre-SCT MBL levels corresponded to recipients' genotypes (P<0.001), changed significantly post-SCT, but were not influenced by donors' genotypes. MBL oligomer profiles were similar pre-/post-SCT. Cultured CD34+ cells were found not to synthesise MBL. In conclusion, low MBL levels pre-transplant predisposed patients to sepsis, fungal and viral infection. Donors' MBL genotypes did not influence infection rates. Prospective studies should clarify the importance of MBL as a prelude for MBL replacement after SCT.

Published
2010
Full Text
View/download PDF

30. Interactive diagnostics in the indication to allogeneic SCT in AML.

Author

Bacher U, Haferlach C, Schnittger S, Kern W, Kroeger N, Zander AR, and Haferlach T

Subjects
Cytodiagnosis, Diagnostic Techniques and Procedures, Humans, Leukemia, Myeloid, Acute therapy, Molecular Diagnostic Techniques, Nucleophosmin, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute diagnosis
Abstract

Owing to the heterogeneity of AML, the indication for allogeneic SCT (allo-SCT) requires an exact definition of the individual subentity and risk category. A comprehensive diagnostic approach is needed, which combines cytomorphology, cytogenetics, FISH, molecular genetics and immunophenotyping. Whereas the categorization in three prognostic karyotype groups is well established, rare recurrent aberrations as the unfavorable t(8;16)(p11;p13), inv(3)(q21q26) and t(6;9)(p23;q34) must also be considered. In normal karyotype, PCR analyses reveal prognostically relevant mutations in >85% of cases, and a molecular data set composed of the FLT3-ITD, MLL-PTD, NPM1 and CEBPA mutations was found able to guide the selection of patients for allo-SCT. Some novel markers as the WT1 mutations might further contribute to risk stratification in normal karyotype. The panel of minimal residual disease parameters is being expanded at this time, for example, by quantitative PCR for the NPM1 mutations. Immunophenotyping allows the definition of leukemia-associated phenotypes in nearly all cases, but its position in the indication to allo-SCT has to be validated. Thus, the optimization of the indication to allo-SCT is an ongoing process that should remain in continuous interaction with the increasing panel of known genetic markers and diagnostic methods.

Published
2009
Full Text
View/download PDF

31. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.

Author

Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, and Bacher U

Subjects
Acyclovir therapeutic use, Antiviral Agents therapeutic use, Bacterial Infections epidemiology, Child, Epstein-Barr Virus Infections drug therapy, Graft vs Host Disease epidemiology, Histocompatibility Testing, Humans, Immunosuppression Therapy, Middle Aged, Mycoses epidemiology, Parasitic Diseases epidemiology, Tissue Donors, Epstein-Barr Virus Infections epidemiology, Herpesvirus 4, Human growth & development, Stem Cell Transplantation adverse effects, Virus Activation
Abstract

Fatal problems encountered in allogeneic stem cell transplantation include EBV reactivation and post transplant lymphoproliferative disorders (PTLDs) with high mortality rates. We performed a retrospective analysis in all consecutive adult and pediatric EBV reactivations and PTLD during a period of 8.5 years. There were 26 patients with EBV reactivation/PTLD out of a total of 854 transplantations giving an overall incidence of 3.0%. Specifically, the incidence of EBV-PTLD was 1.3%, whereas that of EBV reactivation was 1.8%. Median age was 46.0 and 11.0 years in the adult and pediatric patients, respectively. There were high rates (54%) of concomitant bacterial, viral, fungal and parasitic infections at the time of EBV manifestation. Variable treatment regimens were applied including in most cases an anti-CD20 regimen often in combination with virustatic compounds, polychemotherapy or donor lymphocytes. The mortality rates were 9 of 11 (82%) in patients with EBV-PTLD and 10 of 15 (67%) in patients with reactivation. Only 7 of 26 patients (27%) are alive after a median follow-up of 758 days (range 24-2751). The high mortality rates of EBV reactivation and of EBV-PTLD irrespective of multimodal treatment approaches emphasize standardization and optimization of post transplant surveillance and treatment strategies to improve control of these often fatal complications.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results